Is GlaxoSmithKline plc More Likely To Double In Value Than Hikma Pharmaceuticals Plc?

GlaxoSmithKline plc (LON:GSK) is less likely to deliver higher returns than Hikma Pharmaceuticals Plc (LON:HIK) over the medium term, argues Alessandro Pasetti.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) and Hikma Pharmaceuticals (LSE: HIK) have been under the spotlight for different reasons this week. The shares of both have risen, yet Hikma is the one that has sent a clear message to investors: as it bulks up, its 10-year rally may last for a very long time..!

Glaxo, meanwhile, must shrink to deliver rapidly rising returns to its shareholders. 

Glaxo: A More Aggressive Strategy Is Needed

Glaxo’s market value has risen 4.5% from its one-year lows since Wednesday, when a decent trading update confirmed 2015 earnings guidance and the outlook for 2016. The HIV and consumer healthcare businesses fared better than the reminder of its portfolio, but its second-quarter results were a mixed bag — and analysts did not buy into its story.

S&P Capital IQ, Society Generale and Deutsche Bank joined those in the bear camp, downgrading the stock soon after the results came out. Going with estimates from these three brokers, the shares would be fairly valued somewhere in the region of 1,250p and 1,450p. Glaxo stock currently trades at 1,390p, but market consensus estimates assign to it a possible valuation of 1,500p, according to Thomson Reuters estimates.

There’s merit in a view that suggests limited capital appreciation: assuming Glaxo reports underlying operating income at between £6bn and £7bn annually until 2017, while maintaining a steady operating margin at 25% over the period, the value of its stock plus net debt per share would be about 12/13 times the value of its forward Ebit. Its underlying profits could be lower, though, which would push up its relative valuation based on weaker fundamentals. Consider that the shares of Shire, for instance, trade at 20x based on the same metric, but on stronger fundamentals. 

To achieve a much higher valuation, Glaxo needs to report higher margins, a steeper growth rate for its operating income or a combination of both — or, alternatively, it should spin off its prized assets. Otherwise, it may well continue to be a decent yield play — the dividend is covered by core earnings — but I doubt capital gains could be meaningful. 

Hikma is a different story. 

Hikma’s Stellar Performance 

There was always a chance that the shares of Hikma would have enjoyed a great run on the market even before the announcement of its $2.65bn acquisition of Roxane Laboratories and Boehringer Ingelheim Roxane on Tuesday.  

Its core earnings were expected to grow on average at 20% a year into 2017. Which means that, assuming constant trading multiples, its shares could have reach 3,268p from 2,100p — the price at which its stock traded before the acquisition of the US specialty generic drugs business was announced.

The deal, which shows a wise capital allocation strategy and an appropriate cash/equity financing mix, contributed to a 15% rise in its stock price this week. 

Even though its valuation was already a tad rich before this week’s rise — considering the growth rate for sales, earnings and margins since 2013 — its seven-year operating performance has been truly impressive, boosted by acquisitions, which play a very important role in its corporate strategy. Consider that since the business was floated in 2005, its stock’s performance reads 762%. 

It may take less now to record a similar performance.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro Pasetti has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline and Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »